Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and
investigate whether changes in gene expression, or the expression of specific biomarkers, are
either predictive of response to bevacizumab or indicative of response.